Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2024, Healio covered several stories about trials ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor ...

Vision loss can reduce your independence and may lead to isolation, anxiety, and depression. Taking steps such as talking with a therapist and seeking support can help you manage your mental health.

Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy. Ryan Haumschild, PharmD, MS, MBA: Hello, and welcome to this AJMC® Peer Exchange®program ...

Geographic atrophy (GA) is an advanced dry form of age-related macular degeneration (AMD). Up to 20% of folks with AMD may get it. While we see GA across all populations and races, it’s more common in ...

In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a real-world study in eyes with geographic atrophy due to nonexudative age-related macular degeneration.Ip, of Doheny Eye ...

Maybe you’ve noticed that you can no longer see your friends and family clearly. Or perhaps it’s becoming increasingly hard — if not impossible — to drive yourself to your favorite restaurant.

An Iveric Bio drug at the heart of a $5.9 billion Astellas Pharma acquisition has received FDA approval, making it just the second approved therapy for a common vision loss-disorder that afflicts an ...